Literature DB >> 15651908

Zolpidem: a review of its use in the management of insomnia.

Tracy Swainston Harrison1, Gillian M Keating.   

Abstract

Zolpidem (Ambien, Stilnox, Myslee, an imidazopyridine, is a nonbenzodiazepine hypnotic indicated for the short-term treatment of insomnia. Zolpidem improves sleep in patients with insomnia. Its overall tolerability is favourable when administered according to the manufacturer's prescribing information, with a low propensity to cause clinical residual effects, withdrawal, dependence or tolerance. In addition, most evidence suggests that the drug is associated with minimal rebound insomnia. In the only clinical trials that investigated the use of a hypnosedative drug in an 'as-needed' regimen, zolpidem produced a global improvement in sleep. Thus, zolpidem continues to be a useful therapeutic option in the pharmacological treatment of patients with insomnia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15651908     DOI: 10.2165/00023210-200519010-00008

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  74 in total

1.  Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening.

Authors:  Ian Hindmarch; Alain Patat; Neil Stanley; Isabelle Paty; Una Rigney
Journal:  Hum Psychopharmacol       Date:  2001-03       Impact factor: 1.672

2.  Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.

Authors:  J Fry; M Scharf; R Mangano; M Fujimori
Journal:  Int Clin Psychopharmacol       Date:  2000-05       Impact factor: 1.659

3.  A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia.

Authors:  S Tsutsui
Journal:  J Int Med Res       Date:  2001 May-Jun       Impact factor: 1.671

Review 4.  Insomnia: therapeutic approach.

Authors:  S Lippmann; I Mazour; H Shahab
Journal:  South Med J       Date:  2001-09       Impact factor: 0.954

5.  Antagonizing the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem.

Authors:  R Cluydts; J De Roeck; P Cosyns; P Lacante
Journal:  J Clin Psychopharmacol       Date:  1995-04       Impact factor: 3.153

6.  [Safety profile of zolpidem: two studies of 3805 patients by Swiss practitioners].

Authors:  E Ganzoni; M Gugger
Journal:  Praxis (Bern 1994)       Date:  1999-06-24

7.  Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.

Authors:  Joris C Verster; Edmund R Volkerts; Antonia H C M L Schreuder; Erik J E Eijken; Janet H G van Heuckelum; Dieuwke S Veldhuijzen; Marinus N Verbaten; Isabelle Paty; Mona Darwish; Philippe Danjou; Alain Patat
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

Review 8.  Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

Authors:  Y Dündar; A Boland; J Strobl; S Dodd; A Haycox; A Bagust; J Bogg; R Dickson; T Walley
Journal:  Health Technol Assess       Date:  2004-06       Impact factor: 4.014

9.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

Authors:  D J Greenblatt; J S Harmatz; L L von Moltke; B L Ehrenberg; L Harrel; K Corbett; M Counihan; J A Graf; M Darwish; P Mertzanis; P T Martin; W H Cevallos; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1998-11       Impact factor: 6.875

10.  Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots.

Authors:  B A Sicard; S Trocherie; J Moreau; H Vieillefond; L A Court
Journal:  Aviat Space Environ Med       Date:  1993-05
View more
  31 in total

Review 1.  Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Elisabeth Polard; Yvette Akwa; Alain Patat
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Zolpidem extended release in insomnia: profile report.

Authors:  Marit D Moen; Greg L Plosker
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

4.  Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects.

Authors:  Eui Hyun Jung; Choong-Min Lee; Ji-Yeong Byeon; Hyo-Bin Shin; Kyung-Yul Oh; Chang-Keun Cho; Chang Woo Lim; Choon-Gon Jang; Seok-Yong Lee; Yun Jeong Lee
Journal:  Arch Pharm Res       Date:  2020-07-13       Impact factor: 4.946

5.  Use of non-benzodiazepine sedative hypnotics and risk of falls in older men.

Authors:  Susan J Diem; Susan K Ewing; Katie L Stone; Sonia Ancoli-Israel; Susan Redline; Kristine E Ensrud
Journal:  J Gerontol Geriatr Res       Date:  2014-07-01

6.  General and efficient copper-catalyzed three-component coupling reaction towards imidazoheterocycles: one-pot synthesis of alpidem and zolpidem.

Authors:  Natalia Chernyak; Vladimir Gevorgyan
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-01       Impact factor: 15.336

Review 7.  Sublingual zolpidem (Edluar™; Sublinox™).

Authors:  Lily P H Yang; Emma D Deeks
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

8.  Increased relative risk of acute pancreatitis in zolpidem users.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

9.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

10.  Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans.

Authors:  Cheng-Tai Li; Tung-Ping Su; Yanfeng Wang; Benjamin Lee; Melvin Toh; Tony Ho
Journal:  J Clin Sleep Med       Date:  2016-11-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.